A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (NCT07015242)

🧪 Interventions in This Study

• Rituximab (DRUG)
• Methotrexate (DRUG)
• Procarbazine (DRUG)
• Temozolomide (DRUG)
• Liso-cel (BIOLOGICAL)
• Fludarabine (DRUG)
• Cyclophosphamide (DRUG)
• Calcium folinate (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (40 Sites)

Showing the first 25 of 40 sites.

• University Of Colorado — Aurora, Colorado
• Moffitt Cancer Center — Tampa, Florida
• Robert H. Lurie Comprehensive Cancer Center of Northwestern University — Chicago, Illinois
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Washington University School of Medicine in St. Louis — St Louis, Missouri
• Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
• Roswell Park Comprehensive Cancer Center — Buffalo, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Cleveland Clinic — Cleveland, Ohio
• The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
• University of Pennsylvania — Philadelphia, Pennsylvania
• Sarah Cannon Research Institute Oncology Partners — Nashville, Tennessee
• MD Anderson Cancer Center — Houston, Texas
• Fred Hutchinson Cancer Center — Seattle, Washington
• Local Institution - 0111 — Nice, Alpes-Maritimes
• Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu — Nantes, Loire-Atlantique
• Local Institution - 0103 — Pierre-Bénite, Rhône
• CHU de Dijon Bourgogne - Hopital Francois Mitterand — Dijon,
• Chru De Lille - Hopital Claude Huriez — Lille,
• Local Institution - 0112 — Marseille,
• CHU Montpellier — Montpellier,
• Local Institution - 0114 — Paris,
• Local Institution - 0102 — Paris,
• Local Institution - 0108 — Pessac,
• CHU de Rennes - Hopital de Pontchaillou — Rennes,

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lymphoma

• A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients — New York, New York
• A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — La Jolla, California
• Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma — Calgary, Alberta
• Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma — Anchorage, Alaska
• A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant — New York, New York
• Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL — Chapel Hill, North Carolina

Explore by condition: All Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.